ARA-290 (Cibinetide)
Also known as: Cibinetide · Cibinetida · pHBSP
A short synthetic peptide derived from erythropoietin, studied for tissue protection and neuropathic pain without erythropoietin's blood effects.
ARA-290 (Cibinetide) at a glance
| Name | ARA-290 (Cibinetide) |
|---|---|
| Also known as | Cibinetide, Cibinetida, pHBSP |
| Category | Recovery & tissue repair |
| Type | Peptide |
| Sequence | Short synthetic 11-amino-acid peptide modeled on a region of erythropoietin |
| Typical dose | ~2-4 mg per day |
| Frequency | Once daily in reported studies |
| Route | Subcutaneous injection (research) |
| Half-life | Very short - minutes to a few hours. |
Overview
ARA-290, also called cibinetide, is an 11-amino-acid peptide designed to mimic a tissue-protective region of the erythropoietin molecule while avoiding effects on red blood cell production. It is commonly cited in the research literature for context on the innate repair receptor and neuroinflammation. It has been examined in early clinical studies, including work on sarcoidosis-associated small-fiber neuropathy, though evidence remains preliminary.
How it’s thought to work
- Targets the innate repair receptor (a complex involving the beta-common receptor).
- Appears to modulate inflammation and support tissue protection.
- Studied for effects on nerve fiber density and neuropathic pain.
- Does not meaningfully stimulate erythropoiesis, unlike erythropoietin itself.
Researched uses
- Small-fiber neuropathy in sarcoidosis (clinical research)
- Neuropathic pain modeling
- Anti-inflammatory tissue-protection studies
- Metabolic and diabetic complication research
Commonly cited protocol
| Typical dose | ~2-4 mg per day |
|---|---|
| Frequency | Once daily in reported studies |
| Route | Subcutaneous injection (research) |
| Notes | Trial protocols have used daily dosing over several weeks. |
Reconstitution
Commonly a 4 mg vial; 4 mg in 2 mL gives 2 mg/mL, so a 4 mg dose is about 100 units on a U-100 syringe.
ARA-290 (Cibinetide) dosage calculator
The calculator below is pre-filled with ARA-290 (Cibinetide)’s commonly cited vial size and dose. Adjust the vial amount, bacteriostatic water, or dose to match your own vial — it will show the exact insulin-syringe units to draw, the concentration, and how many doses the vial holds.
Add 2 mL of bacteriostatic water to your 4 mg vial. That gives you about 1 doses of 4000 mcg. For each dose, draw 200 units into a 100-unit insulin syringe.
See the full ARA-290 (Cibinetide) dosing chart (units for every dose & water amount), or open the full peptide calculator →
Cautions
- Not an approved drug; investigational and sold as a research chemical.
- Human data come from small early-phase studies.
- Long-term safety is not established.
- Source purity varies.
ARA-290 (Cibinetide) FAQ
What is ARA-290 (Cibinetide)?
A short synthetic peptide derived from erythropoietin, studied for tissue protection and neuropathic pain without erythropoietin's blood effects.
How does ARA-290 (Cibinetide) work?
Targets the innate repair receptor (a complex involving the beta-common receptor). Appears to modulate inflammation and support tissue protection. Studied for effects on nerve fiber density and neuropathic pain. Does not meaningfully stimulate erythropoiesis, unlike erythropoietin itself.
What is ARA-290 (Cibinetide) used for?
Small-fiber neuropathy in sarcoidosis (clinical research); Neuropathic pain modeling; Anti-inflammatory tissue-protection studies; Metabolic and diabetic complication research.
What is a typical ARA-290 (Cibinetide) dose?
~2-4 mg per day, Once daily in reported studies, Subcutaneous injection (research). This is a commonly cited figure for context only, not medical advice.
How do you reconstitute ARA-290 (Cibinetide)?
Commonly a 4 mg vial; 4 mg in 2 mL gives 2 mg/mL, so a 4 mg dose is about 100 units on a U-100 syringe.
What is the half-life of ARA-290 (Cibinetide)?
Very short - minutes to a few hours.